Patient Reported Outcome on Genital Sensitivity and Sexual Function After Genital Gender Affirming Surgery (PROGAS)
Primary Purpose
Gender Dysphoria
Status
Recruiting
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Semmes-Weinstein monofilament testing and questionnaires
Sponsored by
About this trial
This is an interventional treatment trial for Gender Dysphoria focused on measuring Phalloplasty, Metoidioplasty, Vaginoplasty, Vulvoplasty
Eligibility Criteria
Inclusion Criteria:
- Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations
- Patient age ≥ 18 years
- Transgender male, female of gender non-conforming patient with diagnosed gender dysphoria and the specific wish to undergo genital gender affirming surgery
- Fit for operation, based on the surgeon's expert opinion
- Patient is able and willing to attend the follow-up consultations
Exclusion Criteria:
- Absence of signed written informed consent and thus a patient unwilling to participate.
- Patient age < 18 years
- Cisgender patients
- Patients unfit for operation
- Patient declares that it will be impossible for him to attend the follow-up consultations
Sites / Locations
- University Hospital GhentRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Genital sensation and sexual functioning assessment
Arm Description
Genital sensation testing with clinical assessment and self-examination questionnaire. Sexual functioning testing with questionnaires.
Outcomes
Primary Outcome Measures
Change in genital sensitivity pattern at 24 months
Mapping of pressure thresholds of Semmes-Weinstein monofilaments in pre-defined areas of the neo-genital area
Secondary Outcome Measures
Change in postoperative sexual function
Assessed with Male Sexual Health Questionnaire/Female Sexual Function Index questionnaires (MSHQ/FSFI) with added questions specifically on penetrative sexual activity
Change in self-assessment of genital anatomy and genital sensitivity
Assessed with Self-Assessment of Genital Anatomy and Sexual Function (Male and Female) questionnaires (SAGASF-M/SAGASF-F)
Change in voiding function
Assessed with International Consultation on Incontinence Questionnaire on Male and Female Lower Urinary Tract Symptoms (ICIQ-MLUTS/ICIQ-FLUTS)
Change in urinary continence
Assessed with International Consultation on Incontinence Questionnaire on Urge Incontinence short form questionnaire (ICIQ-UI SF)
Change in maximum flow rate
Assessed by uroflowmetry (Qmax)
Change in satisfaction with life by Likert and VAS scales
Assessed with Satisfaction with life scale (SWLS) questionnaire
Change in satisfaction with life by Likert and VAS scales
Assessed with Subjective happiness scale (SHS) questionnaire
Change in quality of life assessed by Likert scales.
Assessed by the EuroQol questionnaire EQ-5D-3L.
Change in quality of life assessed by VAS scale.
Assessed by the EuroQol questionnaire EQ-VAS (0-100)
Subjective patient satisfaction with surgical and functional outcome assessed by Likert scales.
Assessed with seven subjective patient satisfaction questions on different surgical and functional outcomes aspects using Likert scales
Patient motivations for surgery and extent to which these expectations were met as a result of the operation assessed by VAS scales
Assessed with fourteen motivational questions using VAS scales (0-100)
Postoperative complication rate
Categorized according to Clavien-Dindo classification system
Full Information
NCT ID
NCT04993469
First Posted
June 4, 2021
Last Updated
December 19, 2022
Sponsor
University Hospital, Ghent
1. Study Identification
Unique Protocol Identification Number
NCT04993469
Brief Title
Patient Reported Outcome on Genital Sensitivity and Sexual Function After Genital Gender Affirming Surgery
Acronym
PROGAS
Official Title
Patient Reported Outcome on Genital Sensitivity and Sexual Function After Genital Gender Affirming Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 27, 2021 (Actual)
Primary Completion Date
December 31, 2030 (Anticipated)
Study Completion Date
December 31, 2030 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Ghent
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
For genital gender affirming surgery, it remains unclear to what extent genital sensitivity might be expected and what the impact of this might be on sexual functioning.
Detailed Description
Gender dysphoria refers to an inner mental unrest resulting from an incongruity between the assigned biological sex and the mentally experienced sex. The generally accepted treatment for gender dysphoria aims to bring a person's physical characteristics in line with his or her perceived gender identity. This gender-affirming treatment consists of a combination of psychological counselling, hormonal therapy and, if desired, genital gender-affirming surgery. This involves the removal of the biological reproductive organs and in some cases (part of) the biological sex organs. These can be replaced by surrogate sex organs of the desired sex while maintaining urological and sexual function. In transgender women, this is achieved with vulvoplasty or vaginoplasty, while in transgender men, metoidioplasty or phalloplasty is performed.
While urological functioning is an extensively studied topic in transgender patients after genital gender confirmation surgery, sexual functioning is often considered of secondary importance, even though it is one of the goals of gender confirmation surgery. In the transgender man, a phalloplasty is performed using microsurgical techniques that allow the nerves of the donor flap (usually from the forearm or upper leg) to be connected to the genital and inguinal nerves. In metoidioplasty, the clitoris is preserved and forms the base of a micro-penis. In the transgender woman, the glans penis is partially preserved to create a clitoris. The purpose of this is to achieve maximum sensitivity of the genital area.
There are few reports in the literature demonstrating sensory recovery in these extensively operated body parts, let alone what the added value on sexual functioning might be as a result of this recovery of genital sensitivity. At Ghent University Hospital, we now have more than 30 years' experience with such operations and have shared this experience in an almost entirely retrospective manner in various publications to date. However, in order to address the bias associated with retrospective research, this study aims to prospectively and observationally collect data on these patients who are counseled in a pathway for gender dysphoria. This study will include all patients - after informed consent - and will collect specific data on surgical outcome (complications after surgery, duration of surgery, type of surgery) and functional outcome (tailored questionnaires for patients undergoing such a treatment with questions on urination, erections, sexual experience, quality of life, patient satisfaction and genital sensitivity) for each of these various surgical options. These outcomes will be verified at follow-up moments (after 3 months, 6 months, 12 months and 24 months). Specifically for the component on genital sensitivity, we plan to follow up patients 3-monthly by means of a Semmes-Weinstein monofilament test of the genital region up to 24 months postoperatively. The aim of this study is therefore to use this prospectively collected data to truthfully map our experience, to be critical, to reflect and optimize our daily clinical practice in the interest of the patient.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gender Dysphoria
Keywords
Phalloplasty, Metoidioplasty, Vaginoplasty, Vulvoplasty
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Single group assignment Single centre open label prospective
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Genital sensation and sexual functioning assessment
Arm Type
Experimental
Arm Description
Genital sensation testing with clinical assessment and self-examination questionnaire.
Sexual functioning testing with questionnaires.
Intervention Type
Diagnostic Test
Intervention Name(s)
Semmes-Weinstein monofilament testing and questionnaires
Intervention Description
Semmes-Weinstein test for the assessment of genital sensation Battery of questionnaires assessing sexual function, voiding function, quality of life and patient satisfaction
Primary Outcome Measure Information:
Title
Change in genital sensitivity pattern at 24 months
Description
Mapping of pressure thresholds of Semmes-Weinstein monofilaments in pre-defined areas of the neo-genital area
Time Frame
Baseline function test, followed by reassessment at 3, 6, 9, 12, 15, 18, 21 and 24 months of follow-up
Secondary Outcome Measure Information:
Title
Change in postoperative sexual function
Description
Assessed with Male Sexual Health Questionnaire/Female Sexual Function Index questionnaires (MSHQ/FSFI) with added questions specifically on penetrative sexual activity
Time Frame
Baseline questionnaire, followed by reassessment at 12 and 24 months of follow-up
Title
Change in self-assessment of genital anatomy and genital sensitivity
Description
Assessed with Self-Assessment of Genital Anatomy and Sexual Function (Male and Female) questionnaires (SAGASF-M/SAGASF-F)
Time Frame
Baseline questionnaire, followed by reassessment at 3, 6, 9, 12, 15, 18, 21 and 24 months of follow-up
Title
Change in voiding function
Description
Assessed with International Consultation on Incontinence Questionnaire on Male and Female Lower Urinary Tract Symptoms (ICIQ-MLUTS/ICIQ-FLUTS)
Time Frame
Baseline questionnaire, followed by reassessment at 3, 6, 12 and 24 months of follow-up
Title
Change in urinary continence
Description
Assessed with International Consultation on Incontinence Questionnaire on Urge Incontinence short form questionnaire (ICIQ-UI SF)
Time Frame
Baseline questionnaire, followed by reassessment at 3, 6, 12 and 24 months of follow-up
Title
Change in maximum flow rate
Description
Assessed by uroflowmetry (Qmax)
Time Frame
Uroflowmetry at baseline, followed by uroflowmetry at 3, 6, 12 and 24 months of follow-up
Title
Change in satisfaction with life by Likert and VAS scales
Description
Assessed with Satisfaction with life scale (SWLS) questionnaire
Time Frame
Baseline questionnaire, followed by reassessment at 3, 6, 12 and 24 months of follow-up
Title
Change in satisfaction with life by Likert and VAS scales
Description
Assessed with Subjective happiness scale (SHS) questionnaire
Time Frame
Baseline questionnaire, followed by reassessment at 3, 6, 12 and 24 months of follow-up
Title
Change in quality of life assessed by Likert scales.
Description
Assessed by the EuroQol questionnaire EQ-5D-3L.
Time Frame
Baseline questionnaire, followed by reassessment at 3, 6, 12 and 24 months of follow-up
Title
Change in quality of life assessed by VAS scale.
Description
Assessed by the EuroQol questionnaire EQ-VAS (0-100)
Time Frame
Baseline questionnaire, followed by reassessment at 3, 6, 12 and 24 months of follow-up
Title
Subjective patient satisfaction with surgical and functional outcome assessed by Likert scales.
Description
Assessed with seven subjective patient satisfaction questions on different surgical and functional outcomes aspects using Likert scales
Time Frame
Assessed at 12 and 24 months of follow-up
Title
Patient motivations for surgery and extent to which these expectations were met as a result of the operation assessed by VAS scales
Description
Assessed with fourteen motivational questions using VAS scales (0-100)
Time Frame
Baseline questions, followed by reassessed at 12 and 24 months of follow-up
Title
Postoperative complication rate
Description
Categorized according to Clavien-Dindo classification system
Time Frame
Within 90 days postoperatively
10. Eligibility
Sex
All
Gender Based
Yes
Gender Eligibility Description
The study is specific to patients with gender dysphoria who wish to undergo genital gender affirming surgery.
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
110 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations
Patient age ≥ 18 years
Transgender male, female of gender non-conforming patient with diagnosed gender dysphoria and the specific wish to undergo genital gender affirming surgery
Fit for operation, based on the surgeon's expert opinion
Patient is able and willing to attend the follow-up consultations
Exclusion Criteria:
Absence of signed written informed consent and thus a patient unwilling to participate.
Patient age < 18 years
Cisgender patients
Patients unfit for operation
Patient declares that it will be impossible for him to attend the follow-up consultations
Facility Information:
Facility Name
University Hospital Ghent
City
Ghent
State/Province
East-Flanders
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wietse Claeys, MD
Phone
003293321702
Email
wietse.claeys@uzgent.be
First Name & Middle Initial & Last Name & Degree
Nicolaas Lumen, MD, PhD
Phone
003293322276
Email
nicolaas.lumen@uzgent.be
First Name & Middle Initial & Last Name & Degree
Anne-Françoise Spinoit, MD, PhD
First Name & Middle Initial & Last Name & Degree
Nicolaas Lumen, MD, PhD
First Name & Middle Initial & Last Name & Degree
Wietse Claeys, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Patient Reported Outcome on Genital Sensitivity and Sexual Function After Genital Gender Affirming Surgery
We'll reach out to this number within 24 hrs